[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-nasopharyngeal-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-nasopharyngeal-carcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,40,66,94,117,143,171,191,212,236],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100622839","phase-2-timing-optimization-of-immunotherapy-during-neoadjuvant-chemotherapy-for-locally-advanced-nasopharyngeal-carcinoma-100622839",false,"NCT07388836","Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma","A Multicenter, Randomized, Phase II Clinical Trial to Optimize the Timing of Immune Checkpoint Inhibitor Administration During Neoadjuvant Chemotherapy in Patients With Locally Advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Age between 18 and 70 years\n\nHistologically confirmed locoregionally advanced nasopharyngeal carcinoma (AJCC\u002FUICC 8th edition stage II-III)\n\nAt least one measurable target lesion per RECIST 1.1\n\nECOG performance status of 0-1\n\nEstimated life expectancy ≥ 6 months\n\nAdequate hematologic, hepatic, renal, and coagulation function\n\nNegative pregnancy test for women of childbearing potential\n\nWillingness to use effective contraception during the study and for 12 months after treatment\n\nSigned informed consent\n\nWilling and able to comply with study procedures\n\nNot participating in any other interventional clinical trials during the study period\n\nExclusion Criteria:\n\n* re first dose\n\nActive or suspected autoimmune disease requiring systemic treatment\n\nOngoing systemic immunosuppressive therapy\n\nActive hepatitis B, hepatitis C, HIV infection, or other serious infections\n\nHistory of another malignancy within 5 years (except non-melanoma skin cancer or in situ cervical cancer)\n\nPregnant or breastfeeding women\n\nInability or unwillingness to use contraception as required\n\nLife expectancy \\\u003C 6 months","ALL","18 Years","70 Years",{"count":20,"type":21},198,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a multicenter, open-label, randomized phase II clinical trial designed to evaluate the optimal timing of toripalimab administration during neoadjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Participants will receive gemcitabine and cisplatin (GP) chemotherapy combined with toripalimab administered on different days (Day 1, Day 5, or Day 9) to compare treatment responses. The neoadjuvant phase includes 3 cycles of 21 days each, followed by concurrent chemoradiotherapy. The estimated enrollment period is from March 2026 to March 2028.",[27],"Locally Advanced Nasopharyngeal Carcinoma","NOT_YET_RECRUITING","2026-01-28",{"date":31,"type":32},"2026-02-05","ACTUAL",{"date":34,"type":21},"2026-03-01",{"date":36,"type":21},"2028-05",{"name":38,"class":39},"Fujian Cancer Hospital","OTHER_GOV",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100432379","phase-2-consolidation-nivolumab-after-concurrent-chemoradiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-100432379","NCT04910347","Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma","A Phase 2, Open-label Trial of Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Male or female\n2. Age (at the time of informed consent): 19 years and older\n3. Subjects with histologically- or cytologically-confirmed advanced Nasopharyngeal cancer (Stage II -IVa) according to 8th edition clinical staging system of the American Joint Committee on Cancer before the start of concurrent chemoradiotherapy\n4. Patients who have recovered from previous toxicities of standard chemoradiotherapy (Grade ≤1).\n5. ECOG (Eastern Cooperative Oncology Group) Performance Status Score 0 or 1\n6. Patients with a life expectancy of at least 3 months\n7. Patients whose latest laboratory data meet the below criteria within 7 days before registration. If the date of the laboratory tests at the time of registration is not within 7 days before the first dose of the investigational product, testing must be repeated within 7 days before the first dose of the investigational product, and these latest laboratory tests must meet the following criteria. Of note, laboratory data will not be valid if the patient has received a granulocyte colony-stimulating factor (G-CSF) or blood transfusion within 14 days before testing.\n\n   * White blood cells ≥2,000\u002Fmm3 and neutrophils ≥1,500\u002Fmm3\n   * Platelets ≥100,000\u002Fmm3\n   * Hemoglobin ≥9.0 g\u002FdL\n   * AST (GOT) and ALT (GPT) ≤3.0-fold the upper limit of normal (ULN) of the study site (or ≤5.0-fold the ULN of the study site in patients with liver metastases)\n   * Total bilirubin ≤1.5-fold the ULN of the study site\n   * Creatinine ≤1.5-fold the ULN of the study site or creatinine clearance (either the measured or estimated value using the Cockcroft-Gault equation) \\>45 mL\u002Fmin\n8. Women of childbearing potential (including women with chemical menopause or no menstruation for other medical reasons) #1 must agree to use contraception#2 from the time of informed consent until 5 months or more after the last dose of the investigational product. Also, women must agree not to breastfeed from the time of informed consent until 5 months or more after the last dose of the investigational product.\n9. Men must agree to use contraception#2 from the start of study treatment until 7 months or more after the last dose of the investigational product.\n\n   * Women of childbearing potential are defined as all women after the onset of menstruation who are not postmenopausal and have not been surgically sterilized (e.g., hysterectomy, bilateral tubal ligation, bilateral oophorectomy). Postmenopause is defined as amenorrhea for ≥12 consecutive months without specific reasons. Women using oral contraceptives, intrauterine devices, or mechanical contraception such as contraceptive barriers are regarded as having childbearing potential.\n   * The subject must consent to use any two of the following methods of contraception: vasectomy or condom for patients who are male or female subject's partner and tubal ligation, contraceptive diaphragm, intrauterine device, spermicide, or oral contraceptive for patients who are female or male subject's partner.\n\nExclusion Criteria:\n\n1. Patients with multiple primary cancers (with the exception of completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer, or any other cancer that has not recurred for at least 5 years)\n2. Patients with residual adverse effects of prior therapy or effects of surgery that would affect the safety evaluation of the investigational product in the opinion of the investigator or sub-investigator.\n3. Patients with current or past history of severe hypersensitivity to any other antibody products\n4. Patients with concurrent autoimmune disease or history of chronic or recurrent autoimmune disease\n5. Patients with a current or past history of interstitial lung disease or pulmonary fibrosis diagnosed based on imaging or clinical findings. Patients with radiation pneumonitis may be randomized if the radiation pneumonitis has been confirmed as stable (beyond acute phase) without any concerns about recurrence.\n6. Patients with concurrent diverticulitis or symptomatic gastrointestinal ulcerative disease\n7. Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment. Patients may be randomized if the metastasis is asymptomatic and requires no treatment.\n8. Patients with pericardial fluid, pleural effusion, or ascites requiring treatment\n9. Patients with uncontrollable, tumor-related pain\n10. Patients who have experienced a transient ischemic attack, cerebrovascular accident, thrombosis, or thromboembolism (pulmonary arterial embolism or deep vein thrombosis) within 180 days before registration\n11. Patients with a history of uncontrollable or significant cardiovascular disease meeting any of the following criteria:\n\n    * Myocardial infarction within 180 days before registration\n    * Uncontrollable angina pectoris within 180 days before registration\n    * New York Heart Association (NYHA) Class III or IV congestive heart failure\n    * Uncontrollable hypertension despite appropriate treatment (e.g., systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥ 90 mmHg lasting 24 hours or more)\n    * Arrhythmia requiring treatment\n12. Patients receiving or requiring anticoagulant therapy for a disease. Patients receiving antiplatelet therapy including low-dose aspirin may be enrolled.\n13. Patients with uncontrollable diabetes mellitus\n14. Patients with systemic infections requiring treatment\n15. Patients who have received systemic corticosteroids (except for temporary use, e.g., for examination or prophylaxis of allergic reactions) or immunosuppressants within 28 days before registration\n16. Patients who have received antineoplastic drugs (e.g., chemotherapy agents, molecular-targeted therapy agents, or immunotherapy agents) within 28 days before registration\n17. Patients who have undergone surgical adhesion of the pleura or pericardium within 28 days before registration\n18. Patients who have undergone surgery under general anesthesia within 28 days before registration\n19. Patients who have undergone surgery involving local or topical anesthesia within 14 days before registration\n20. Patients who have received radiotherapy within 28 days before registration, or radiotherapy to bone metastases within 14 days before registration\n21. Patients who have received any radiopharmaceuticals (except for examination or diagnostic use of radiopharmaceuticals) within 56 days before registration\n22. Patients with a positive test result for any of the following: HIV-1 antibody, HIV-2 antibody, HTLV-1 antibody, HBs antigen, or HCV antibody (except if HCV-RNA negative)\n23. Patients with a negative HBs antigen test but a positive test result for either HBs antibody or HBc antibody with a detectable level of HBV-DNA\n24. Women who are pregnant or breastfeeding, or possibly pregnant\n25. Patients who have received any other unapproved drug (e.g., investigational use of drugs, unapproved combined formulations, or unapproved dosage forms) within 28 days before registration\n26. Patients who have previously received Nivolumab, anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, anti-CTLA-4 antibody or other therapeutic antibodies or pharmacotherapies for regulation of T-cells\n27. Patients judged to be incapable of providing consent for reasons such as concurrent dementia\n28. Other patients judged by the investigator or sub-investigator to be inappropriate as subjects of this study\n29. Patient with current or past history of hypersensitivity to Nivolumab.","MALE","19 Years",{"count":50,"type":21},57,[24],"The clinical efficacy of nivolumab for locally advanced nasopharyngeal carcinoma patients with residual disease after standard chemoradiotherapy is not known. In this study, we aim to investigate the role of nivolumab in locally advanced NPC after chemoradiotherapy the safety profile and antitumor activity of the anti-programmed death 1 (PD-1) receptor monoclonal antibody, nivolumab after in patients with advanced nasopharyngeal carcinoma",[27],"RECRUITING","2026-01-23",{"date":57,"type":32},"2026-01-27",{"date":59,"type":32},"2022-02-07",{"date":61,"type":21},"2026-05",{"name":63,"class":64},"Yonsei University","OTHER",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":65},"100606583","phase-3-serplulimab-combined-with-induction-chemotherapy-and-radiotherapy-in-nasopharyngeal-carcinoma-100606583","NCT07177443","Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma","Induction Chemotherapy Combined With Serplulimab Induction\u002FMaintenance Therapy and Omission of Concurrent Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma (UNION-NPC-001): A Multicenter, Open-Label, Randomized, Controlled, Phase III, Non-Inferiority Clinical Trial","Inclusion Criteria:\n\n1. Age at diagnosis: 18-65 years;\n2. Pathologically confirmed treatment-naïve nasopharyngeal carcinoma of \"non-keratinizing type (WHO classification)\";\n3. Locoregionally advanced nasopharyngeal carcinoma staged per the 9th edition of the American Joint Committee on Cancer (AJCC) staging system: Stage II (T1-3N2), Stage III(T1-4N3 or T4N1-2);\n4. ECOG performance status: 0-1;\n5. Post-induction therapy requirements:\n\n   Radiological assessment showing ≥50% tumor regression (RECIST 1.1) Undetectable plasma EBV DNA levels;\n6. Adequate bone marrow function:\n\n   White blood cell count \\>4×10⁹\u002FL Hemoglobin \\>90 g\u002FL Platelet count \\>100×10⁹\u002FL;\n7. Normal hepatic\u002Frenal function:\n\n   Total bilirubin ≤1.5×upper limit of normal (ULN) AST\u002FALT ≤2.5×ULN Alkaline phosphatase ≤2.5×ULN Creatinine clearance ≥60 mL\u002Fmin;\n8. Normal results for:\n\n   Thyroid function tests Amylase and lipase Pituitary function Inflammatory\u002Finfection markers Cardiac enzymes Electrocardiogram\n\n   Additional requirements:\n\n   Pulmonary function tests for smokers \\>50 years Cardiac ultrasound + myocardial function tests for patients with ECG abnormalities or cardiovascular history (unless meeting exclusion criterion (8));\n9. Signed informed consent with willingness\u002Fcompliance to follow study schedules for treatment, follow-up, and laboratory tests;\n10. For women of childbearing potential: Agreement to use reliable contraception (e.g., condoms, prescribed oral contraceptives) from screening until 1 year post-treatment.\n\nExclusion Criteria:\n\n1. Hepatitis B Virus (HBV) Infection:\n\n   HBsAg-positive with HBV DNA \\>1×10³ copies\u002FmL (patients with controlled viremia \\[\\\u003C1×10³ copies\u002FmL\\] after antiviral therapy are eligible).\n2. Hepatitis C Virus (HCV) Infection: Anti-HCV antibody-positive.\n3. HIV\u002FAIDS: Anti-HIV antibody-positive or diagnosed with acquired immunodeficiency syndrome (AIDS).\n4. Active Tuberculosis (TB): History of active TB within the past year (regardless of treatment status). Exception: Patients with adequately treated past TB (confirmed by standard anti-TB therapy) may be enrolled if \\>1 year since completion of treatment.\n5. Active Autoimmune Diseases:Known or suspected autoimmune disorders (e.g., uveitis, colitis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, hypothyroidism, or asthma requiring bronchodilators).\n\n   Exceptions:\n\n   Type 1 diabetes mellitus Hypothyroidism managed with hormone replacement Skin conditions not requiring systemic therapy (e.g., vitiligo, psoriasis, alopecia).\n6. Interstitial Lung Disease (ILD):\n\n   History of ILD or pneumonitis requiring oral\u002FIV steroids within the past year.\n7. Immunosuppressive Therapy:\n\n   Chronic systemic corticosteroids (≥10 mg prednisone equivalent\u002Fday) or other immunosuppressants within 4 weeks prior to enrollment. Inhaled\u002Ftopical steroids are permitted.\n8. Uncontrolled Cardiac Disease: Heart failure (NYHA class ≥2), Unstable angina, Myocardial infarction within the past year, Clinically significant arrhythmias requiring treatment.\n9. Pregnancy\u002FLactation: Pregnant or breastfeeding women (urine\u002Fblood pregnancy test required for women of childbearing potential).\n10. Concurrent Malignancies:\n\n    History of other malignancies except:\n\n    Adequately treated non-melanoma skin cancer, Carcinoma in situ of the cervix, Papillary thyroid carcinoma.\n11. Hypersensitivity: Known allergy to any component of the study drugs or excipients.\n12. Active Infections:\n\n    Systemic infections requiring treatment within 1 week prior to enrollment.\n\n    Live Vaccines:\n13. Administration of live vaccines within 30 days before the first immunotherapy dose.\n14. Organ Transplantation: History of allogeneic organ transplantation.\n15. Other High-Risk Conditions:\n\nAny condition that may compromise patient safety or compliance per investigator assessment (e.g., severe psychiatric disorders, life-threatening comorbidities, or social\u002Ffamilial risk factors).","65 Years",{"count":75,"type":21},456,[77],"PHASE3","This phase III trial aims to evaluate the efficacy and safety of induction chemotherapy combined with serplulimab (induction\u002Fmaintenance therapy) with omission of concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma (LA-NPC).",[27],[81,82,83,84],"Cisplatin-based concurrent chemoradiotherapy","radiotherapy","Treatment De-escalation","locally advanced nasopharyngeal carcinoma","2025-09-16",{"date":87,"type":32},"2025-09-17",{"date":89,"type":21},"2025-09-25",{"date":91,"type":21},"2031-12-31",{"name":93,"class":64},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":65},"100599495","phase-2-iparomlimabtuvorlimab-ql1706-and-modified-tpf-regimen-for-induction-therapy-in-lanpc-100599495","NCT07085234","Iparomlimab\u002FTuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC","The Efficacy and Safety of Iparomlimab\u002FTuvorlimab (QL1706) Combined With Modified TPF Regimen for Induction Therapy in Locally Advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Age: ≥ 18 years old;\n* Patients with nasopharyngeal carcinoma diagnosed by pathology (including histology or cytology), with a clinical stage of III - IV (excluding T3N0 - 1) (according to the UICC\u002FAJCC TNM staging system (8th edition));\n* No prior systematic treatment (surgery, radiotherapy, chemotherapy, etc.); At least one measurable lesion on imaging examination (according to RECIST criteria version 1.1);\n* ECOG PS: 0 - 1 points;\n* Expected survival time ≥ 3 months;\n* Normal function of major organs, meeting the following criteria:\n\n  1. Blood routine tests should meet the following (without blood transfusion within 14 days):\n\n     1. HB ≥ 100 g\u002FL,\n     2. WBC ≥ 3 × 10⁹\u002FL,\n     3. ANC ≥ 1.5 × 10⁹\u002FL,\n     4. PLT ≥ 100 × 10⁹\u002FL;\n  2. Biochemical tests should meet the following criteria:\n\n     1. BIL \\\u003C 1.5 times the upper limit of normal (ULN),\n     2. ALT and AST \\\u003C 2.5 ULN, GPT ≤ 1.5 × ULN;\n     3. Serum Cr ≤ 1 ULN, endogenous creatinine clearance rate \\> 60 ml\u002Fmin (Cockcroft - Gault formula);\n* Male subjects and women of childbearing potential must use contraception from the start of the first dose of the study drug until 24 weeks after the last dose of the study drug;\n* Normal function of major organs, with basically normal blood routine, blood biochemistry and coagulation function tests;\n* The investigator believes that the patient will benefit from the treatment in terms of survival;\n* The patient voluntarily participates in this study and provides a written informed consent form.\n\nExclusion Criteria:\n\n* Active, known, or suspected autoimmune diseases;\n* Patients with hypertension whose blood pressure cannot be controlled within the normal range with antihypertensive medications (systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 90 mmHg);\n* Inherited bleeding tendency or coagulation disorders. Clinically significant bleeding symptoms occurred within 12 weeks before screening or there is a definite bleeding tendency (cumulative blood loss exceeding 50 ml within 24 hours);\n* Uncontrolled cardiac clinical symptoms or diseases, such as: (1) Heart failure of NYHA class II or above; (2) Unstable angina; (3) Myocardial infarction within 24 weeks; (4) Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n* Interstitial lung disease, drug-induced pneumonia, radiation pneumonia requiring steroid treatment, active pneumonia with clinical symptoms, or severe pulmonary function impairment;\n* Subjects with active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 10⁴ copies\u002FmL) or hepatitis C (positive for hepatitis C antibody and HCV-RNA above the lower limit of detection of the analytical method);\n* Subjects with allergic reactions to the drugs used in this study;\n* Pregnant or lactating women;\n* Other conditions considered by the investigator as unsuitable for participation in this study.",{"count":102,"type":21},30,[24],"This is a prospective, open-label, multicenter, single-arm clinical study. A total of 30 patients with locally advanced nasopharyngeal carcinoma who have not received prior systemic treatment are planned to be enrolled at three centers. After enrollment, the patients will receive induction therapy with Iparomlimab\u002FTuvorlimab(QL-1706) in combination with a modified TPF regimen, followed by concurrent chemoradiotherapy with cisplatin according to the standards of clinical practice.",[27,106,107],"Immunotherapy","Induction Therapy","2025-07-17",{"date":110,"type":32},"2025-07-25",{"date":112,"type":21},"2025-07-30",{"date":114,"type":21},"2029-12-31",{"name":116,"class":64},"The First Affiliated Hospital of Xiamen University",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":130,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":65},"100573907","phase-2-sintilimab-combined-with-bevacizumab-and-tp-chemotherapy-in-the-treatment-of-high-risk-locally-advanced-npc-100573907","NCT06752382","Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC","Sintilimab Combined With Bevacizumab and Induction Chemotherapy in the Treatment of High Risk Advanced Nasopharyngeal Carcinoma Prospective, Single-arm, Multicenter Phase II Clinical Study","Inclusion Criteria:\n\n1. Signed a written informed consent form (ICF) voluntarily.\n2. Male or female, aged from 18 to 75 years.\n3. Histologically newly diagnosed patients with differentiated or undifferentiated non-keratinous carcinoma (according to World Health Organization \\[WHO\\] histological types).\n4. Patients with tumor stage TanyN2-3M0 (according to AJCC Edition 8).\n5. ECOG score 0-1.\n6. Adequate bone marrow\u002Fliver and kidney function\u002Fheart and lung and other physiological function reserves, expected to successfully complete chemoradiotherapy and immunotherapy.\n\nExclusion Criteria:\n\n1. subjects with pathologically diagnosed adenocarcinoma or sarcoma of the nasopharynx.\n2. subject has other malignancy within 3 years prior to first dose except nasopharyngeal carcinoma. Subjects with other malignancies that have been cured by local therapy, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ, are excluded.\n3. Participated in treatment with an investigational drug or used an investigational device within 4 weeks prior to the first dose.\n4. active or previous definite inflammatory bowel disease (e.g., Crohn 's disease or ulcerative colitis) disease.\n5. History of immunodeficiency; positive HIV antibody test; current chronic use of systemic corticosteroids or other immunosuppressive agents; local, ocular, intra-articular, intranasal, and inhaled corticosteroids are allowed.\n6. Patients who are pregnant or nursing (for women of childbearing age, pregnancy testing should be considered and the use of effective contraception during treatment should be emphasized).\n7. Subjects with known active pulmonary tuberculosis (TB) and suspected active TB require clinical examination to rule out; known active syphilis infection.\n8. known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation; 9. history of pneumonitis\u002Finterstitial lung disease requiring systemic corticosteroids or current pneumonitis.\n9. serious infections within 4 weeks prior to the first dose, including but not limited to comorbidities requiring hospitalization, sepsis, or serious pneumonia; active infections (excluding antiviral therapy for hepatitis B or C) that have received systemic anti-infective therapy within 2 weeks prior to the first dose.\n10. Subjects with untreated active hepatitis B (HBsAg positive and HBV-DNA more than 1000 copies\u002Fml \\[200 IU\u002Fml\\] or above the lower limit of detection) and anti-hepatitis B virus treatment during study treatment are required for subjects with hepatitis B; subjects with active hepatitis C (HCV antibody positive and HCV-RNA level above the lower limit of detection).\n11. any of the following cardiovascular and cerebrovascular diseases: a) myocardial infarction, unstable angina pectoris, cerebrovascular accident, transient ischemic attack, acute or persistent myocardial ischemia, symptomatic heart failure (Grade 2 and above according to the New York Heart Association functional classification), or any arterial thromboembolic event within 6 months before the first dose; b) history of venous thromboembolic events (NCI CTCAE 5.0 version 3 and above), pulmonary embolism, or other serious thromboembolism within 3 months before the first dose; c) presence of serious arrhythmia requiring long-term drug intervention; patients with asymptomatic atrial fibrillation with stable ventricular rate are allowed; d) presence of aortic aneurysm, aortic dissecting aneurysm, internal carotid artery stenosis and other major vascular diseases that may be life-threatening or require surgery within 6 months; e) previous history of myocarditis or cardiomyopathy.\n12. Known hypersensitivity to any component of any study drug; known history of serious hypersensitivity to other monoclonal antibodies.\n\n13 known history of mental illness, drug abuse, alcoholism, or drug abuse; 15. pregnant or lactating women. 16. Any previous or current illness, treatment, or laboratory abnormality that may confound the results of the study, affect the subject 's full participation in the study, or that participation may not be in the subject' s best interest.","75 Years",{"count":126,"type":21},58,[24],"Nearly half of the world's nasopharyngeal cancer occurs in China, among which the highest incidence in Guangdong and Guangxi, so the nickname \"Guangdong tumor\". Due to the hidden position of the nasopharynx, 70% to 80% of patients are found in the middle and late stages. Immunotherapy plays a significant role in nasopharyngeal carcinoma. Professor Ma Jun of Sun Yat-sen University reported a phase 3 clinical study at ASCO meeting in 2023, which compared the efficacy of Sintilimab combined with GP chemotherapy versus GP chemotherapy alone in locally advanced nasopharyngeal carcinoma, and the results showed that EFS in the immune group decreased by 41% in 3 years. The risk of local recurrence-free survival and distant metastasis was reduced by 48% and 43%, respectively. However, a subgroup analysis of the study found that low-risk patients benefited more, while N2-N3 patients benefited only HR There is 0.78, new treatment options need to be explored in clinic. Therefore, the investigators plan to initiate a prospective study to evaluate the efficacy and safety of Sintilimab Combined With Bevacizumab and TP Chemotherapy for high-risk locally advanced nasopharyngeal carcinoma.",[27],[131,132,133],"PD-1","Bevacizumab","TP Chemotherapy","2024-12-21",{"date":136,"type":32},"2024-12-30",{"date":138,"type":21},"2024-12-31",{"date":140,"type":21},"2027-12-31",{"name":142,"class":64},"Zhejiang Cancer Hospital",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":170},"100507820","effect-of-immunonutrients-on-oral-mucositis-in-nasopharyngeal-carcinoma-patients-after-chemoradiotherapy-100507820","NCT05892354","Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy","Efficacy of Immunonutrients in Reducing Oral Mucositis in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Prospective, Multicenter, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n2. Age 18-70 years old, male or non-pregnant women;\n3. Pathologically confirmed non-keratinizing carcinoma of the nasopharynx (differentiated or undifferentiated,WHO type II or III);\n4. Newly diagnosed stage III-IVa (8th AJCC\u002FUICC stage) NPC patients;\n5. The levels of major organ function meet the following criteria:\n\n(1)Hematology: WBC ≥ 3.0 × 10\\^9\u002FL, ANC ≥ 1.5 × 10\\^9\u002FL, PLT ≥ 100 × 10\\^9\u002FL, HGB ≥ 90 g\u002FL; (2) Liver function: ALT, AST≤2.5 times the upper limit of normal (ULN), total bilirubin ≤ 1.5 × ULN; (3) Renal function: BUN and CRE ≤ 1.5 × ULN or an estimated glomerular filtration rate (eGFR) ≥ 60 ml\u002Fmin (calculated using the Cockcroft-Gault equation); (4) Adequate coagulation function: defined as an international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times the ULN; (5) Normal levels of cardiac enzymes; 6. The patient has signed informed consent forms and is able to comply with the study's planned visits, treatment plans, and laboratory tests.\n\nExclusion Criteria:\n\n1. History of investigational Oral Impact®\u002FENSURE® use within the month prior to enrollment;\n2. Known allergy or intolerance to any component of investigational Oral Impact®\u002FENSURE® or related chemotherapy drugs;\n3. Poor glycemic control in patients with diabetes;\n4. Patients with autoimmune diseases;\n5. Patients with active infections;\n6. Patients who have received radiation therapy or other anti-tumor treatments in the past;\n7. Patients with a history of other malignant tumors;\n8. Presence of oral mucositis at baseline;\n9. Malnutrition at baseline;\n10. Patients who cannot eat the required amount of food at baseline and require parenteral or enteral nutrition;\n11. Inability to eat soft solid foods at baseline;\n12. History of human immunodeficiency virus (HIV) or active hepatitis B\u002FC virus infection;\n13. Participation in other intervention clinical studies within one month;\n14. Subjects deemed by the investigator to have other factors that may force them to terminate the study, such as having other serious illnesses (including mental illnesses) that require concomitant treatment, significantly abnormal laboratory test results, or family or social factors that may affect subject safety or data collection.",{"count":151,"type":21},190,[153],"NA","The purpose of this study was to investigate the role of immunonutrion compared with standard nutrition in reducing oral mucositis in patients with locally advanced nasopharyngeal carcinoma.",[27],[157,158,159,160],"Immunonutrition","Nasopharyngeal Carcinoma","Chemoradiotherapy","Oral Mucositis","2024-08-05",{"date":163,"type":32},"2024-08-07",{"date":165,"type":32},"2023-06-12",{"date":167,"type":21},"2027-04-01",{"name":169,"class":64},"First Affiliated Hospital of Guangxi Medical University",20,{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":4},"100553765","phase-2-gp-combined-with-nimotuzumab-and-sintilimab-as-induction-therapy-for-nasopharyngeal-carcinoma-100553765","NCT06490341","GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma","Safety and Efficacy of GP Regimen Combined With Nimotuzumab and Sintilimab as Induction Therapy in Locally Advanced Nasopharyngeal Carcinoma: a Single-center, Prospective, Single-arm Phase II Clinical Study","Inclusion Criteria:\n\n1. Age between 18 and 75 years, inclusive, without gender restriction.\n2. ECOG Performance Status (PS) score of 0 or 1.\n3. Histologically confirmed diagnosis of locally advanced nasopharyngeal carcinoma, staged as III-IVa according to the 2018 American Joint Committee on Cancer (AJCC) staging system, with T3-4N2M0 or T1-4N3M0 classification. Tumor types include WHO type II and III.\n4. Presence of at least one measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and patients who have not undergone definitive treatment.\n5. Expected survival duration of at least 3 months.\n6. White blood cell count ≥ 3 × 10\\^9\u002FL; absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; platelet count ≥ 100 × 10\\^9\u002FL; hemoglobin level ≥ 90 g\u002FL.\n7. Serum creatinine level ≤ 1.2 mmol\u002FL or creatinine clearance ≥ 60 ml\u002Fmin.\n8. Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN) (in case of liver metastasis, ≤ 3.0 × ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (in case of liver metastasis, ≤ 5.0 × ULN).\n9. Female patients must have a negative urine pregnancy test prior to study enrollment (this criterion does not apply to patients with bilateral ovarian resection and\u002For hysterectomy or postmenopausal patients).\n10. Signed written informed consent form.\n\nExclusion Criteria:\n\n1. Subjects who have received radiotherapy, chemotherapy, immunosuppressive agents, monoclonal antibodies, oral epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), or anti-angiogenic drugs within the past six months.\n2. Subjects who have participated in another interventional clinical trial, undergone major surgical procedures, or scheduled for surgery within 30 days prior to screening.\n3. Patients with severe underlying diseases that preclude tolerance to the treatment.\n4. History of other malignancies, except for cured cervical carcinoma in situ, skin basal cell carcinoma, or malignancies cured for more than 5 years without recurrence.\n5. Presence of uncontrolled comorbidities such as heart failure, diabetes mellitus, hypertension, thyroid disorders, psychiatric illnesses, etc.\n6. Subjects with contraindications to immunotherapy, including those with immune dysfunction diseases (such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus, HIV infection, hepatitis B, hepatitis C, chronic use of steroids for autoimmune diseases), recipients of allogeneic transplants, patients with interstitial lung disease, or those with meningeal metastasis or progressive brain metastasis.\n7. Allergy to any of the drugs or their components used in the study protocol.\n8. Grade 2 or higher peripheral neuropathy or hearing loss according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.\n9. Pregnant women (confirmed by blood or urine human chorionic gonadotropin \\[HCG\\] test) or lactating mothers, or subjects of reproductive age who are unwilling or unable to adopt effective contraceptive measures until at least 6 months after the last treatment in the study.\n\n   \\-",{"count":170,"type":21},[24],"The goal of this clinical trial is to learn if the regimen of gemcitabine, cisplatin combined with nimotuzumab and sintilimab works to treat locally advanced nasopharyngeal carcinoma before chemoradiotherapy. It will also learn about the safety of the regimen. The main questions it aims to answer are:\n\n* Does the regimen increase the number of participants who has a significant tumor shrinkage?\n* What medical problems do participants have when taking the regimen? Researchers will evaluate the safety and efficacy of the regimen.\n\nParticipants will:\n\n* Take the regimen every 21 days, for twice.\n* Visit the clinic weekly for drug administration, checkups and tests.\n* Keep a diary of their symptoms.",[27],"2024-06-29",{"date":184,"type":32},"2024-07-08",{"date":186,"type":21},"2024-07-20",{"date":188,"type":21},"2027-07-20",{"name":190,"class":64},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":65},"100505400","phase-3-two-cycles-vs-three-cycles-induction-chemotherapy-in-t1-4n2-3-locally-advanced-nasopharyngeal-carcinoma-100505400","NCT05860868","Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma","Two Cycles VS Three Cycles Induction Chemotherapy Plus Concurrent Chemoradiotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Age 18-65 years old;\n2. Pathologically confirmed non-keratinizing nasopharyngeal carcinoma;\n3. Stage T3-4N0-1 (according to the UICC\u002FAJCC 8th);\n4. No distant metastasis;\n5. Have not received anti-cancer treatment in the past;\n6. ECOG (Eastern Cooperative Oncology Group of the United States): 0-1;\n7. Adequate hematologic, hepatic and renal function.\n\nExclusion Criteria:\n\n1. The purpose of treatment is palliative;\n2. Diagnosed with other malignant tumors at the same time;\n3. Malignant tumor history;\n4. Pregnancy or breastfeeding, or expect to become pregnant during the clinical trial period;\n5. Combined serious illness.",{"count":199,"type":21},474,[77],"This trial is a multi-center phase III clinical trial. The purpose of this trial is to explore whether 2 cycles induction chemotherapy combined with concurrent chemoradiotherapy is not inferior to 3 cycles induction chemotherapy combined with concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.",[27],"2023-05-06",{"date":205,"type":32},"2023-05-16",{"date":207,"type":21},"2023-05",{"date":209,"type":21},"2030-05",{"name":211,"class":64},"First Affiliated Hospital, Sun Yat-Sen University",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":65},"100469819","phase-2-envafolimab-plus-chemoradiotherapy-for-locally-advanced-npc-a-prospective-single-armed-phase-ii-trial-100469819","NCT05397769","Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.","Envafolimab Plus Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma, a Prospective, Single Armed Phase II Trial.","Inclusion Criteria:\n\n* ECOG 0-1\n* histologically confirmed non-keratinizing carcinoma (WHO type II or III) of nasal pharynx\n* stage III-IVa （AJCC\u002FUICC 8th ）, untreated NPC patients\n* NE≥ 1.5×10E9\u002FL, HGB ≥ 100g\u002FL and PLT ≥100×10E9\u002FL\n* ALT≤ 1.5 upper limit of normal (ULN), AST≤ 1.5ULN and bilirubin ≤ 1.5ULN\n* creatinine\\\u003C1.5×ULN\n\nExclusion Criteria:\n\n* recurrent or metastatic NPC patients\n* histologically confirmed keratinizing carcinoma (WHO type I) of nasal pharynx\n* already received radiation or chemotherapy\n* pregnant or lactating women, or women of childbearing age without birth control\n* HIV (+)\n* had other cancers before\n* used immune checkpoint inhibitor(CTLA-4、PD-1、PD-L1 etc.) before\n* complications requiring long-term treatment with immunosuppressive drugs or systemic or local use of corticosteroids with immunosuppressive dose\n* with immune deficiency diseases, or a history of organ transplantation (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism and hypothyroidism; Patients with vitiligo or asthma in childhood who have completely relieved and do not need any intervention after adulthood can be included; Asthma requiring medical intervention with bronchodilators cannot be included)\n* use of massive dose of glucocorticoids within 4 weeks before enrollment\n* laboratory test values do not meet relevant standards within 7 days before enrollment\n* significantly lower functions of heart, liver, lung, kidney and bone marrow\n* serious or uncontrolled medical diseases or infections\n* participating other clinical trial in the same time\n* HBsAg (+) and HBV DNA \\>1×10E3 copiers \u002FmL\n* HCV (+) unless HCV RNA PCR(-)\n* with any other treatment contraindications",{"count":220,"type":21},36,[24],"Patients diagnosed with locally advanced nasopharyngeal carcinoma will be recruited in this study. All the patients will get 3 cycles of GP+ Envafolimab for the induction chemotherapy. After that, the patients will receive concurrent chemoradiotherapy. Radiotherapy will be given by IMRT, under the dose of GTVnx 68-70Gy\u002F30-33f, 5d\u002Fw,6-7w, during which, every patient would receive 2 cycles of DDP+Envafolimab as concurrent chemotherapy. Then patients would receive Envafolimab every 3 weeks for maintenance treatment for a year, until disease progression or intolerance of treatment. . We aim to evaluate the three years progression free survival of these patients by the combination of Envafolimab with curative chemoradiotherapy.",[27,224,225,226],"Envafolimab","Induction Chemotherapy","PD-L1","2022-08-09",{"date":229,"type":32},"2022-08-10",{"date":231,"type":32},"2022-06-08",{"date":233,"type":21},"2026-12-31",{"name":235,"class":64},"Sun Yat-sen University",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":65},"100444021","phase-3-iccrt-vs-crt-for-locally-advanced-nasopharyngeal-carcinoma-100444021","NCT05062005","ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma","Induction Chemotherapy+Chemoradiotherapy vs. Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma",{"count":243,"type":21},447,[77],"This trial is a multi-center phase III clinical trial. The purpose of this trial is to explore whether concurrent chemoradiotherapy is not inferior to induction chemotherapy combined with concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.",[27],"2021-09-21",{"date":249,"type":32},"2021-09-30",{"date":251,"type":21},"2021-09-22",{"date":253,"type":21},"2027-08-31",{"name":211,"class":64}]